BioSpace News Archive

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update.

MetrioPharm AG, a pharmaceutical development company, welcomes Sven Zimmermann, as its new Chief Financial Officer, bringing more than a decade of experience in strategic transactions.

The Fund has now invested a total of USD 30 million in six companies

Hardy Diagnostics has begun production of triple-bagged, irradiated SterEM™ mono plates and Lok-Tight™ irradiated contact plates with new package enhancements.

Orion Biotechnology Canada Ltd. announced that In vitro potency assessment of their lead compound, OB-002, has demonstrated that the chemokine analogue is more potent than other CCR5 antagonists in development for HIV prevention and cancer indications.

In the early 1980s, Genentech produced the first biotech drug – insulin.

Renowned Cancer Researcher to Support Ongoing Clinical Studies to Further Demonstrate the Safety and Efficacy of NAD+

EpiCypher, Inc. announces the commercial licensing of ChIC (University of Geneva) and CUT&RUN / CUT&Tag (Fred Hutchinson Cancer Research Center) technologies.

An article published in Experimental Biology and Medicine reports that noninvasive imaging techniques can be used to study eye development.

Retrophin, Inc. announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets.